Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity after radioembolization with yttrium-90 resin microspheres

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Melucci, Elisa ^a   Cosimelli, Maurizio ^a   Carpanese, Livio ^a   Pizzi, Giuseppe ^a   Izzo, Francesco ^b   Fiore, Francesco ^b   Golfieri, Rita ^c   Giampalma, Emanuela ^c   Sperduti, Isabella ^a   Ercolani, Cristiana ^a   Sciuto, Rosa ^a   Mancini, Raffaello ^a   Garufi, Carlo ^a   Diodoro, Maria Grazia ^a   Mottolese, Marcella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Malpighi Hospital   (Italy)

Author keywords

Bcl 2; Colorectal cancer; Ki 67; Liver metastases; p53; Radioembolization; Survivin; Yttrium 90 resin microspheres

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; SURVIVIN; YTTRIUM 90;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; HUMAN; LIVER METASTASIS; LIVER PARENCHYMA; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RADIOEMBOLIZATION;

ADOLESCENT; ADULT; AGED; COLORECTAL NEOPLASMS; COMPOSITE RESINS; EMBOLIZATION, THERAPEUTIC; FEMALE; GENES, BCL-2; GENES, P53; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT; YTTRIUM RADIOISOTOPES;

EID: 84874522066     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-13     Document Type: Article

References (28)

1. Epidemiology and management of liver metastases from colorectal cancer. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM, Ann Surg 2006 244 2 254 259 10.1097/01.sla.0000217629.94941.cf 16858188 (Pubitemid 44305540)
2. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, et al. Lancet 2008 371 9617 1007 1016 10.1016/S0140-6736(08) 60455-9 18358928 (Pubitemid 351392040)
3. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, et al. N Engl J Med 2009 360 14 1408 1417 10.1056/NEJMoa0805019 19339720
4. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Van Groeningen CJ, Sinnige HA, et al. N Engl J Med 2009 360 6 563 572 10.1056/NEJMoa0808268 19196673
5. Strategies to convert to resectability the initially unresectable colorectal liver metastases. Popescu I, Alexandrescu S, Croitoru A, Boros M, Hepatogastroenterology 2009 56 91-92 739 744 19621694
6. Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. Cianni R, Pelle G, Notarianni E, Saltarelli A, Rabuffi P, Bagni O, Filippi L, Cortesi E, Eur Radiol 2013 23 1 182 189 10.1007/s00330-012-2556-5 22836160
7. Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Huijbregts JE, van het Schip AD, Elschot M, Bult W, De Jong HW, et al. J Exp Clin Cancer Res 2010 29 70 10.1186/1756-9966-29-70 20550679
8. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C, Int J Radiat Oncol Biol Phys 2004 60 5 1552 1563 10.1016/j.ijrobp.2004.09.004 15590187 (Pubitemid 39601873)
9. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Campbell AM, Bailey IH, Burton MA, Phys Med Biol 2001 46 2 487 498 10.1088/0031-9155/46/2/315 11229728 (Pubitemid 32148511)
10. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, et al. Br J Cancer 2010 103 3 324 331 10.1038/sj.bjc.6605770 20628388
11. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, De Keukeleire K, Verslype C, Defreyne L, Van Cutsem E, et al. J Clin Oncol 2010 28 23 3687 3694 10.1200/JCO.2010.28.5643 20567019
12. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Buglioni S, D'Agnano I, Cosimelli M, Vasselli S, D'Angelo C, Tedesco M, Zupi G, Mottolese M, Int J Cancer 1999 84 6 545 552 10.1002/(SICI)1097-0215(19991222)84:6<545:: AID-IJC1>3.0.CO;2-2 10567896
13. p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. Buglioni S, D'Agnano I, Vasselli S, Perrone Donnorso R, D'Angelo C, Brenna A, Benevolo M, Cosimelli M, Zupi G, Mottolese M, Am J Clin Pathol 2001 116 3 360 368 10.1309/V7UW-UT2E-JVYH-DGWK 11554164 (Pubitemid 32851969)
14. Expression of the antiapoptotic protein survivin in colon cancer. Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D, Clin Colorectal Cancer 2010 10 3 188 193
15. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ, Gut 2000 46 5 645 650 10.1136/gut.46.5.645 10764707 (Pubitemid 30305781)
16. P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: distribution and prognostic relevance. Torsello A, Garufi C, Cosimelli M, Diodoro MG, Zeuli M, Vanni B, Campanella C, D'Angelo C, Sperduti I, Perrone Donnorso R, et al. Eur J Cancer 2008 44 9 1217 1222 10.1016/j.ejca.2008.03.002 18424032
17. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Mollevi DG, Serrano T, Ginesta MM, Valls J, Torras J, Navarro M, Ramos E, Germa JR, Jaurrieta E, Moreno V, et al. Carcinogenesis 2007 28 6 1241 1246 10.1093/carcin/bgm012 17259658 (Pubitemid 47062683)
18. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS, Kemeny N, Paty PB, Ann Surg Oncol 2010 17 2 572 578 10.1245/s10434-009-0605-3 19727962
19. Molecular markers of chemotherapy in advanced colorectal cancer: back to square one. Sobrero A, Eur J Cancer 2009 45 11 1902 1903 10.1016/j.ejca.2009.05. 018 19502051
20. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Koopman M, Venderbosch S, Nagtegaal ID, Van Krieken JH, Punt CJ, Eur J Cancer 2009 45 11 1935 1949 10.1016/j.ejca.2009. 04.023 19473832
21. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Bertolini F, Bengala C, Losi L, Pagano M, Iachetta F, Dealis C, Jovic G, Depenni R, Zironi S, Falchi AM, et al. Int J Radiat Oncol Biol Phys 2007 68 5 1455 1461 10.1016/j.ijrobp.2007.02.018 17445998 (Pubitemid 47176800)
22. Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Terzi C, Canda AE, Sagol O, Atila K, Sonmez D, Fuzun M, Gorken IB, Oztop I, Obuz F, Int J Colorectal Dis 2008 23 1 37 45 17805549 (Pubitemid 350142358)
23. Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. Zlobec I, Vuong T, Compton CC, Lugli A, Michel RP, Hayashi S, Jass JR, Br J Cancer 2008 98 2 450 456 10.1038/sj.bjc.6604172 18182986 (Pubitemid 351161259)
24. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Albanese I, Scibetta AG, Migliavacca M, Russo A, Bazan V, Tomasino RM, Colomba P, Tagliavia M, La Farina M, Biochem Biophys Res Commun 2004 325 3 784 791 10.1016/j.bbrc.2004.10.111 15541358 (Pubitemid 39487940)
25. Cancer cell adaptation to chemotherapy. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, et al. BMC Cancer 2005 5 78 10.1186/1471-2407-5-78 16026610 (Pubitemid 41461055)
26. Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. Tominaga T, Iwahashi M, Takifuji K, Hotta T, Yokoyama S, Matsuda K, Higashiguchi T, Oku Y, Nasu T, Yamaue H, Int J Cancer 2010 126 7 1691 1701 19810096
27. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK, Br J Surg 2007 94 3 274 286 10.1002/bjs.5719 17315288 (Pubitemid 46423843)
28. Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease. Panasiuk A, Dzieciol J, Panasiuk B, Prokopowicz D, World J Gastroenterol 2006 12 38 6198 6202 17036395 (Pubitemid 44688172)